Thermo Fisher Scientific Inc. $TMO Shares Sold by ST Germain D J Co. Inc.

Key Points

• ST Germain D J Co. Inc. significantly reduced its stake in Thermo Fisher Scientific, selling 8,690 shares and lowering its ownership by 70.3%, bringing its total holdings to 3,666 shares worth approximately $1.486 million.
• Several institutional investors, including Brighton Jones LLC and Versant Capital Management Inc., increased their stakes in Thermo Fisher Scientific during the fourth quarter, indicating ongoing interest from major financial entities.
• Thermo Fisher reported earnings of $5.36 per share for its last quarter, surpassing expectations, and announced a quarterly dividend of $0.43 per share, reflecting a 0.4% yield.

ST Germain D J Co. Inc. lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 70.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,666 shares of the medical research company's stock after selling 8,690 shares during the quarter. ST Germain D J Co. Inc.'s holdings in Thermo Fisher Scientific were worth $1,486,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Brighton Jones LLC boosted its stake in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after purchasing an additional 988 shares during the period. Revolve Wealth Partners LLC lifted its holdings in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares in the last quarter. Ameriflex Group Inc. acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at about $30,000. Versant Capital Management Inc increased its position in shares of Thermo Fisher Scientific by 102.6% during the first quarter. Versant Capital Management Inc now owns 1,009 shares of the medical research company's stock worth $502,000 after acquiring an additional 511 shares during the last quarter. Finally, Webster Bank N. A. boosted its holdings in Thermo Fisher Scientific by 0.5% in the first quarter. Webster Bank N. A. now owns 18,489 shares of the medical research company's stock valued at $9,200,000 after purchasing an additional 89 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Analyst Ratings Changes

A number of brokerages have issued reports on TMO. William Blair began coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an "outperform" rating on the stock. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective on the stock in a research note on Friday, July 11th. UBS Group boosted their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Finally, Robert W. Baird boosted their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $588.35.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 400 shares of the company's stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the transaction, the chief executive officer owned 113,762 shares in the company, valued at approximately $56,937,881. This represents a 0.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 over the last quarter. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Price Performance

TMO opened at $464.18 on Friday. The firm has a market cap of $175.28 billion, a price-to-earnings ratio of 26.85, a price-to-earnings-growth ratio of 2.49 and a beta of 0.75. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $623.77. The company's 50-day moving average price is $476.70 and its 200 day moving average price is $448.02. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.